Predicts 1-year risk of major bleeding in patients with atrial fibrillation enrolled in the Global Anticoagulant Registry in the FIELD (GARFIELD-AF) study. Developed to provide a complementary bleeding risk assessment alongside stroke risk estimation (CHA₂DS₂-VASc) to guide anticoagulation decisions in AF.

Parameters

Age

< 60 years (0 pts)+060–74 years (+1 pt)+1≥ 75 years (+2 pts)+2

Sex

Male (0 pts)+0Female (+1 pt)+1

Uncontrolled Hypertension

No / controlled (+0 pts)+0Uncontrolled hypertension (+2 pts)+2

Prior Major Bleeding or Predisposition

No prior bleeding (0 pts)+0Prior major bleeding (+3 pts)+3

Anemia (Hgb < 130 g/L in men, < 120 g/L in women)

No anemia (0 pts)+0Anemia present (+2 pts)+2

Concomitant Antiplatelet Agent Use

No antiplatelet agents (0 pts)+0Antiplatelet use (+1 pt)+1

Diabetes Mellitus

No diabetes (0 pts)+0Diabetes present (+1 pt)+1

Awaiting input

Fill in the parameters to see your result

CalculatorsGARFIELD-AF Bleeding Risk Score

CardiologyScore

GARFIELD-AF Bleeding Risk Score